Microglial activation varies in different models of Creutzfeldt-Jakob disease

被引:77
作者
Baker, CA [1 ]
Lu, ZY [1 ]
Zaitsev, I [1 ]
Manuelidis, L [1 ]
机构
[1] Yale Univ, Sch Med, Sect Neuropathol, New Haven, CT 06510 USA
关键词
D O I
10.1128/JVI.73.6.5089-5097.1999
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Progressive changes in host mRNA expression can illuminate crucial pathogenetic pathways in infectious disease. We examined general and specific approaches to mRNA expression in three rodent models of Creutzfeldt-Jakob disease (CJD), Each of these models displays distinctive neuropathology. Although mRNAs for the chemokine receptor CCR5, the lysosomal protease cathepsin S, and the pleiotropic cytokine transforming growth factor beta 1 (TGF-beta 1) were progressively upregulated in rodent CJD, the temporal patterns and peak magnitudes of each of these transcripts varied substantially among models. Cathepsin S and TGF-beta 1 were elevated more than 15-fold in mice and rats infected with two different CJD strains, but not in CJD-infected hamsters, In rats, an early activation of microglial transcripts preceded obvious deposits of prion protein (PrP) amyloid. However, in each of the three CJD models, the upregulation of CCR5, cathepsin S, and TGF-beta 1 was variable with respect to the onset of PrP pathology. These results show glial cell involvement varies as a consequence of the agent strain and species infected. Although neurons are generally assumed to be the primary sites for agent replication and abnormal PrP formation, microglia may be targeted by some agent strains. In such instances, microglia can both process PrP to become amyloid and can enhance neuronal destruction. Because microglia can participate in agent clearance, they may also act as chronic reservoirs of infectivity, Finally, the results here strongly suggest that TGF-beta 1 can be an essential signal for amyloid deposition.
引用
收藏
页码:5089 / 5097
页数:9
相关论文
共 69 条
[31]   VIREMIA IN EXPERIMENTAL CREUTZFELDT-JAKOB DISEASE [J].
MANUELIDIS, EE ;
GORGACZ, EJ ;
MANUELIDIS, L .
SCIENCE, 1978, 200 (4345) :1069-1071
[32]  
MANUELIDIS EE, 1985, LANCET, V2, P896
[33]   Vaccination with an attenuated Creutzfeldt-Jakob disease strain prevents expression of a virulent agent [J].
Manuelidis, L .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (05) :2520-2525
[34]   ASTROCYTE GENE-EXPRESSION IN CREUTZFELDT-JAKOB DISEASE [J].
MANUELIDIS, L ;
TESIN, DM ;
SKLAVIADIS, T ;
MANUELIDIS, EE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5937-5941
[35]   Evolution of a strain of CJD that induces BSE-like plaques [J].
Manuelidis, L ;
Fritch, W ;
Xi, YG .
SCIENCE, 1997, 277 (5322) :94-98
[36]   VIRAL PARTICLES ARE REQUIRED FOR INFECTION IN NEURODEGENERATIVE CREUTZFELDT-JAKOB-DISEASE [J].
MANUELIDIS, L ;
SKLAVIADIS, T ;
AKOWITZ, A ;
FRITCH, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (11) :5124-5128
[37]   Dapsone to delay symptoms in Creutzfeldt-Jakob disease [J].
Manuelidis, L ;
Fritch, W ;
Zaitsev, I .
LANCET, 1998, 352 (9126) :456-456
[38]   Infectivity and host responses in Creutzfeldt-Jakob disease [J].
Manuelidis, L ;
Fritch, W .
VIROLOGY, 1996, 216 (01) :46-59
[39]   THE DIMENSIONS OF CREUTZFELDT-JAKOB-DISEASE [J].
MANUELIDIS, L .
TRANSFUSION, 1994, 34 (10) :915-928
[40]  
MANUELIDIS L, 1988, CIBA F SYMP, V135, P117